Free Trial
→ Free Ticker: Anthropic's silent partner could soar after record $2 trillion IPO (From Monument Traders Alliance) (Ad)tc pixel
OTCMKTS:INBP

Integrated BioPharma Q4 2025 Earnings Results & Report

Integrated BioPharma logo
$0.19 0.00 (0.00%)
As of 10/9/2026 11:40 AM Eastern

Integrated BioPharma reported Q4 2025 earnings on September 23, 2025. The company reported EPS of -$0.01, while revenue was $14.18 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Integrated BioPharma EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Integrated BioPharma Revenue Results

Actual Revenue
$14.18 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Integrated BioPharma Q4 2025 Earnings FAQ

Integrated BioPharma (OTCMKTS:INBP) reported earnings of -$0.01 per share for Q4 2025. The report was announced on Tuesday, September 23, 2025.

Integrated BioPharma reported revenue of $14.18 million for Q4 2025.

Integrated BioPharma Earnings Headlines

Integrated Biopharma’s Wholly-Owned Subsidiary, Manhattan Drug Company, Inc. Appoints Michael Richtmyer as Head of Operations
August 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/40718/integrated-biopharmas-wholly-owned-subsidiary-manhattan-drug-company-inc-appoints-michael-richtmyer-as-head-of-operations/
Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
February 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67678611-integrated-biopharma-inc-integrated-biopharma-reports-results-for-its-quarter-ended-december-31-2025-200.htm
Free Ticker: Anthropic's silent partner could soar after record $2 trillion IPO
Anthropic's IPO prospectus just leaked, revealing 261 pages tied to a record $2 trillion valuation. Beyond headline backers Amazon and Google, tech analyst Matt McCall has tracked a smaller partner that got in early, before most investors knew Claude existed. Matt calls it a Second IPO opportunity and reveals its name and ticker in a free interview.tc pixel
 |  Monument Traders Alliance (Ad)
Integrated BioPharma Holds 2025 Annual Stockholder Meeting
December 10, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/INBP/pressreleases/36420312/integrated-biopharma-holds-2025-annual-stockholder-meeting/
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
December 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/02/3197639/0/en/rentschler-biopharma-and-coriolis-pharma-announce-strategic-collaboration-for-integrated-biopharma-solutions.html
INBP Integrated BioPharma, Inc.
June 15, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/INBP
See More Integrated BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integrated BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integrated BioPharma and other key companies, straight to your email.

About Integrated BioPharma

Integrated BioPharma (OTCMKTS:INBP), Inc. (OTCMKTS:INBP) is a healthcare products company engaged in the manufacture and distribution of vitamins, nutritional supplements, herbal products, and pharmaceutical products. Its activities are focused on products intended to support general health and wellness.

The company has historically served the U.S. market through a combination of proprietary products, contract manufacturing, and wholesale distribution activities. Its manufacturing capabilities have included a range of product formats, such as capsules, tablets, softgels, liquids, powders, creams, and lotions, depending on customer and product requirements.

Integrated BioPharma’s operations have included the development, production, and distribution of health-related consumer products for its own brands and other businesses. Publicly available information about its current leadership structure, product portfolio, and geographic reach is limited.

View Integrated BioPharma Profile
Earnings Tools